BSI-502

N/A

Report date: 2026/01/08 17:29:21
First In Class

Base Information

Drug NameBSI-502
Drug Alias NameBSI-502ATI-052
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAnti-Thymic stromal lymphopoietinAnti-Interleukin-4 receptors
TargetsThymic stromal lymphopoietinInterleukin-4 receptors
Therapy Area/IndicationsInflammationAutoimmune Diseases of the Nervous System
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPreclinical
Originator CompaniesBiosion Inc
China Registration ClassN/A

Develop Information

Active CompaniesBiosion IncAclaris Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsInflammationAutoimmune Diseases of the Nervous System
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A